Intelligent Bio Solutions

Intelligent Bio Solutions ROE

The Return on Equity (ROE) of Intelligent Bio Solutions (INBS) as of Oct 23, 2026 is -225.57 %. In the previous year, Return on Equity (ROE) was -352.75 % — a change of -36.05% (higher).

ROE

-225.57 %

YoY

-36.05%

Last updated:

In 2026, Intelligent Bio Solutions's return on equity (ROE) was -225.57 %, a -36.05% increase from the -352.75 % ROE in the previous year.

The Intelligent Bio Solutions ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
158.97 USD
Jan 1, 2020
71.61 USD
Jan 1, 2021
-46.74 USD
Jan 1, 2022
-126.89 USD
Jan 1, 2023
-279.86 USD
Jan 1, 2024
-121.94 USD
Jan 1, 2025
-352.75 USD
Jan 1, 2026
-225.57 USD
The Intelligent Bio Solutions ROE history
YEARROEYoY
-225.57 %-36.05%
-352.75 %+189.28%
-121.94 %-56.43%
-279.86 %+120.55%
-126.89 %+171.51%
-46.74 %-165.26%
71.61 %-54.95%
158.97 %+38.56%
114.73 %+1,895.13%
5.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

ROE Details

Decoding Intelligent Bio Solutions's Return on Equity (ROE)

Intelligent Bio Solutions's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Intelligent Bio Solutions's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Intelligent Bio Solutions's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Intelligent Bio Solutions’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Intelligent Bio Solutions stock

Return on Equity (ROE) of Intelligent Bio Solutions is -225.57 % in 2026.

Return on Equity (ROE) of Intelligent Bio Solutions changed from -352.75 % to -225.57 %, representing a -36.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Intelligent Bio Solutions with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions